Buscar
Beigene Ltd
ONCAñadir a la lista de seguimiento
289.990USD
+10.100+3.61%
Cierre 06/29, 16:00（ET）Cotizaciones retrasadas 15 min
29.51BCap. mercado
62.12P/E TTM
Más Datos de Beigene Ltd Compañía
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Información de Beigene Ltd
Símbolo de cotizaciónONC
Nombre de la empresaBeOne Medicines AG
Fecha de salida a bolsaMar 02, 2016
Director ejecutivoOyler (John Victor)
Número de empleados11000
Tipo de seguridadDepository Receipt
Fin del año fiscalMar 02
Direcciónc/o BeOne Medicines I GmbH
CiudadBASEL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postal4051
Teléfono41616851900
Sitio Webhttps://beonemedicines.com/
Símbolo de cotizaciónONC
Fecha de salida a bolsaMar 02, 2016
Director ejecutivoOyler (John Victor)
Ejecutivos de Beigene Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
12.90K
-26.88%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
12.90K
-26.88%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Beigene Ltd?
Los cinco principales accionistas de Beigene Ltd son: Dr. Xiaobin Wu, Ph.D.
¿Cuántas instituciones poseen acciones de Beigene Ltd (ONC)?
A fecha de 2026Q1, 602 instituciones poseen acciones de Beigene Ltd, con un valor de mercado combinado de aproximadamente 40.42M, lo que representa el 36.84% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1961186.00.
¿Cuál es la mayor fuente de ganancias de Beigene Ltd?
El 2026Q1, el segmento empresarial Product generó la ganancia más alta para Beigene Ltd, ascendiendo a 1.37B y representando el 97.35% de la ganancia total.
